Crystallin zeta (CRYZ)

Crystallin zeta (abbreviated as CRYZ) is a taxon-specific, NADPH-dependent quinone oxidoreductase enzyme that shares significant sequence and structural similarity with other crystallins, a family of proteins best known for maintaining lens transparency in the vertebrate eye. While ubiquitous in various tissues (including heart, brain, kidney, liver, pancreas, and lung), CRYZ is only minimally expressed in the human lens, unlike other mammals. CRYZ enzymatically detoxifies quinones and protects cells from oxidative stress by catalyzing the reduction of quinones, using NADPH as a cofactor. In addition to its enzymatic activity, CRYZ can bind to AU-rich elements in the 3'-UTR of certain mRNAs (notably BCL2), stabilizing them and influencing apoptosis regulation. While its mutations or altered expression are linked to some diseases, especially anemia and leukemia via BCL2 regulation, CRYZ is not established as a major therapeutic target, receptor, or druggable protein at this time. The name "crystallin zeta" is sometimes confused with the related but distinct protein CRYZL1 (crystallin, zeta (quinone reductase)-like 1), which is encoded by a different gene (CRYZL1). Note on correctness: The query specifically asked for "crystallin zeta" as a therapeutic target. Crystallin zeta (CRYZ) is not established as a direct therapeutic target (e.g., receptor, enzyme inhibited by drugs), and no drugs are documented to interact with it. It is primarily a metabolic and structural protein. Therefore, is_target: false and is_incorrect: true, since it does not fit the usual definition of a "target" in drug discovery. Distinction from CRYZL1: Do not confuse with “crystallin zeta like 1” (CRYZL1) which is a related, but genetically and functionally distinct protein.

Other names

Zeta-crystallinQuinone oxidoreductase (QOR)QOH-1

NADPH-dependent one-electron reduction of quinones (quinone oxidoreductase activity); mRNA 3'-UTR binding (e.g., BCL2 mRNA stability modulation)